AGTC Announces Agenda for R&D Day on January 28, 2020 in New York

Management and External Thought Leaders to Discuss Data from XLRP and ACHM Phase 1/2 Clinical Trials

Webcast Scheduled from 7:30 am – 12:00 pm ET

GAINESVILLE, Fla. and CAMBRIDGE, Mass., Jan. 21, 2020 (GLOBE NEWSWIRE) -- Applied Genetic Technologies Corporation (Nasdaq: AGTC), a biotechnology company conducting human clinical trials of adeno-associated virus (AAV)-based gene therapies for the treatment of rare diseases, today announced that it will host an R&D Day beginning at 7:30 am ET on Tuesday, January 28, 2020 in New York.

AGTC’s R&D Day will include a review of the recently reported positive interim data from the company’s ongoing Phase 1/2 clinical trial in X-linked retinitis pigmentosa (XLRP) as well as data from the ongoing Phase 1/2 clinical trials in achromatopsia (ACHM), which the company expects to report later this month. The event will also include a review of the company’s manufacturing capabilities and pre-clinical programs and will feature discussions with management, patients and key opinion leaders.

“The positive interim six-month data that we reported earlier this month from our XLRP Phase 1/2 trial demonstrates our ability to develop innovative therapies with the potential to transform patients’ lives. We are confident in our abilities to execute the clinical and regulatory steps necessary to advance those therapies to pivotal trials,” said Sue Washer, President and Chief Executive Officer of AGTC. "We look forward to reviewing with you both the XLRP and ACHM programs and providing physician and patient perspectives about ongoing needs in the treatment of these diseases. We will also discuss our exciting preclinical pipeline candidates, which provide opportunities to expand our ophthalmology portfolio and leverage our gene therapy expertise into new disease areas. We expect that we will have multiple opportunities to build value for patients and shareholders alike in 2020 and are excited to begin the year with the R&D Day.”

As reported on January 9, 2020, interim six-month data from the XLRP Phase 1/2 trial demonstrated a favorable safety profile in all 25 patients dosed to date, with improvements in visual sensitivity for four of eight evaluable centrally dosed patients and stable or improving visual acuity trends in all nine centrally dosed patients.

AGTC R&D Day Featured Discussion Topics:

• Corporate Overview
  ° Sue Washer, AGTC President & CEO 
   
• XLRP Patient Perspective
  ° Rachelle Lin, OD, MS, FAAO, Assistant Professor at Marshall B. Ketchum University and Low Vision Rehabilitation and Acquired Brain Injury clinician at the University Eye Center at Ketchum Health in Anaheim, CA